 Intec Pharma Ltd. NASDAQ: NTEC Intec or the Company today announces the termination of the Feasibility and Option agreement with Novartis for the development of a custom-designed Accordion Pill AP for a proprietary Novartis compound, despite the AP having met the technical and pharmacokinetic PK clinical specifications set forth by Novartis. Novartis, following an internal and revised commercial strategic assessment, advised Intec that this program no longer meets Novartis mid to long-term strategic goals. Novartis agreed to pay Intec Pharma 1.5 million USD on conclusion of the program. 